<SEC-DOCUMENT>0001193125-23-274601.txt : 20231109
<SEC-HEADER>0001193125-23-274601.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109170157
ACCESSION NUMBER:		0001193125-23-274601
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231109
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231393578

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d295346d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as November 9, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d295346dex991.htm">Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 9, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d295346dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g295346g05e74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Completes Enrollment in <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb Trial of Efti and KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre
Phase IIb trial evaluating efti in combination with pembrolizumab </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Efti has FDA Fast Track designation for first-line treatment of HNSCC</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; November</B><B></B><B>&nbsp;9, 2023</B> &#150; <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces the completion of patient enrollment in the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> Phase IIb trial evaluating eftilagimod alpha (efti), its proprietary soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase IIb trial enrolled 171 patients at over 30 centres across the United States, Europe, and Australia to evaluate the safety and efficacy of efti in
combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (Combined Positive Score [CPS] &#8805;1) tumors (Cohort A) and in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumors
(Cohort B). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 138 patients with recurrent or metastatic HNSCC whose tumours express <FONT STYLE="white-space:nowrap">PD-L1</FONT> (CPS &#8805;1)
have been enrolled into the 1:1 randomized Cohort A of the trial evaluating the safety and efficacy of 30mg of efti in combination with 400mg of KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> given every six weeks compared to
400mg of KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> alone. Patients in Cohort A whose tumors express <FONT STYLE="white-space:nowrap">PD-L1</FONT> (CPS <U>&gt;</U>1) are also stratified by CPS
<FONT STYLE="white-space:nowrap">1-19</FONT> and CPS <U>&gt;</U>20, and the clinical results for these three CPS groups will be evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally,
33 patients with recurrent or metastatic HNSCC were enrolled into Cohort B to determine the efficacy and safety of the same combination therapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours (CPS &lt;1). These
patients are not expected to respond to KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> monotherapy, with a typical Overall Response Rate of up to 5%, and therefore were not
randomized.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Due to a higher number of patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &lt;1) who were eligible for and allocated to Cohort B and the number of
patients in screening at the time of achieving the trial&#146;s enrollment goal, the trial enrolled 171 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is
Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary endpoints include Overall Survival, Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. The primary analysis according to the
trial protocol will be performed after all subjects have completed at least three cycles of treatment (18 weeks in total) or discontinued the trial, and all relevant data for the primary endpoint has been collected, cleaned, and analysed. The
Company expects to report data from the trial in H1 CY2024.<STRIKE> </STRIKE> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep,
said: </B>&#147;The completion of patient enrollment in <FONT STYLE="white-space:nowrap">TACTI-003</FONT> represents an important milestone in the clinical development of efti. We hope to build upon the encouraging data previously seen combining
efti with the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> in the second line HNSCC setting. Dr Florian Vogl, our CMO who joined Immutep
earlier this year, will oversee the completion of this important trial.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g295346g05e74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.</B><B></B><B>&nbsp;Florian Vogl, CMO of Immutep, added</B>: &#147;We are very excited to have completed patient
enrollment in this randomised, multi-national trial and look forward to sharing data in the first half of 2024. Head and neck squamous cell carcinomas represent a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat,</FONT></FONT> heterogenous cancer and an area of high unmet need. Our results in the second line setting provide optimism for the potential of efti in combination
with pembrolizumab in the first-line treatment of these aggressive tumours.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head and neck squamous cell carcinoma (HNSCC) is the sixth most common
cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.<SUP STYLE="font-size:75%; vertical-align:top">2,3,4</SUP>&nbsp;It is an aggressive, genetically complex, and difficult to treat cancer.<SUP
STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;Furthermore, HNSCC is associated with high levels of psychological distress and compromised quality of life (QOL).<SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;As such, HNSCC
patients need improved treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eftilagimod alpha was granted Fast Track designation by the FDA in April 2021 for treatment of first-line
HNSCC. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g295346g05e74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous
Cell Carcinoma in <FONT STYLE="white-space:nowrap">KEYNOTE-048:</FONT> Subgroup Analysis by Programmed Death <FONT STYLE="white-space:nowrap">Ligand-1</FONT> Combined Positive Score. <I>Journal of Clinical Oncology</I> 2022 40:21, <FONT
STYLE="white-space:nowrap">2321-2332.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods.<I>&nbsp;Int. J. Cancer</I>&nbsp;144, 1941&#150;1953 (2019). <SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries.<I>&nbsp;CA Cancer J. Clin.</I>&nbsp;68, 394&#150;424 (2018). <SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ferlay, J. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on
Cancer (accessed 18&nbsp;September 2020).<I>&nbsp;IARC</I>&nbsp;https://gco.iarc.fr/today&nbsp;(2018). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alsahafi, E., Begg, K., Amelio, I.<I>&nbsp;et al.</I>&nbsp;Clinical update on head and neck cancer: molecular
biology and ongoing challenges.<I>&nbsp;Cell Death Dis</I>&nbsp;10,&nbsp;540 (2019).&nbsp;<SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Johnson, D.E., Burtness, B., Leemans, C.R.<I>&nbsp;et al.</I>&nbsp;Head and neck squamous cell
carcinoma.<I>&nbsp;Nat Rev Dis Primers</I>&nbsp;6,&nbsp;92 (2020). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep
Limited. </P> <P STYLE="margin-top:240pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g295346g05e74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g295346g05e74.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !U T # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%\4M(^'<UC#JMM<7!NU=D$$:N!MQG.2/[PK<\(^*;3Q;X?MM6LTDBMI@VU9
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MR*\:TO\ :J\*:MXP@\-0VFJ+?R7OV$.T2"/?OV9SOSC/M6][ZG;YGM=-9@N
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M+V2L>S@\*L-3Y?F.HHHKH.X**** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%)0!\W_M50O+J?ATHC,/*N 2 3CE.OY5Z)\"E,?PITR-E97590588/\
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M11_N$UZM_9D33W$QC7S9XUBD?^\JYP/_ !YOSI(=+AM[>**&%$CCB\E%Q]U
M,!<^G3CV% C@=:U?4KS1/!=[I<C?:I%6]D@R,72"U9RA/OD#-5]+\8W&N>/-
M!O[>65-"U&&XM;>!U*[F1!(TC ]\IM'LK5Z);Z+:VXM!';QH+1!%  /]6@7;
M@?AQ1)HMK+<VL[6\9EM69X&QCRV92"0/<$_F:!Z'"ZEJUQ'\/?%\PN76YMY;
MM$;/SQG&5 ]/;ZBKGBEM77QGIR:5,"8=.N;EK.7B.X*RP@ ^C8)PW8UT%UX-
MTN\O'NYK*-YG;>_)VR,!@,R_=)^H/05I-I\;7D=WY:_:4C:)9#U"L5)7\U7\
MJ T//+;Q;/<>#?%^K6,LA>&[D$7F#+08AB##'^P2W'M5J;0X/!M[I%UIE]=S
MRWEY%!-'<7;SK<QL3N?#$@$ [\J!T]*[2WT2SMX;F)+6)([AVDE0*,2,P 8D
M>IP,U3LO!^F:9<K/;6BI*F1&S,S>6#P0@)^7(XX[4/4#C?$7A>";XD:'";O4
M%@OH;F6>&.]E56*A", ,,=:VKC4[^S\;7=M:VCW\2V$3F+S538=[@'GUQ742
MZ7!-?07CQ*US;JR12?W0V,C]!3_L,:WCW0C43N@1I,<E020OYDT >:WMY=ZE
M\.;29GG^U3:V('2*<QN5_M H8]RD8^7Y:NZ]ILFA_#?5HHH[VWD=?NM?/+*,
MD<"0L2/SKL+CPW8W6G_89+5#;>;YWE@D /OW[QCON^:BW\,6%K:S6R0EH)O]
M8DCL^?\ OHF@#D? OF:?X@U6Q07EC96\,;?8M1N?/<,2<2(V6)7"D')ZBLS3
M?%TS>,%U>1[XZ=?W)TY(9+=Q!&@.V*4/C;EI 1GNK*:]'_LF*2\^UO&IN/*:
M$R8^8H2"0?;(S22:':26$5BUM&;.,($BQPH3&W'T(&/I0!Y_XBT^ZU3QIJZ0
MV^J7$]M:6IMVLKT0I"SF7+%2P#?=7J#TK5UZ36?#MGIFJB075\8HK*[M]^V.
M21]H$B^FU_T+5V,-@D-U+<H@$\H5'?N57=C_ -";\Z=>6,=]$L<\:R(K*X4^
MJL"/Y4 4]!TF71])AMIKF6]G7<TD\QY=B<DCVSP!V'%?G]X-9?\ AI"Q^89_
MX2AAC//_ !\&OT6/(KC;?X/^#K35DU2'P]9QZBLWV@7"I\PDW[MWUW<T =G1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "45Y__ ,+R\&?]!N'\C1_PO+P9_P!!N'\C67M8=SE^M4/YT>@45Y__ ,+R
M\&?]!N'\C1_PO+P9_P!!N'\C1[6'</K5#^='H%%>?_\ "\O!G_0;A_(T?\+R
M\&?]!N'\C1[6'</K5#^='H%%>?\ _"\O!G_0;A_(T?\ "\O!G_0;A_(T>UAW
M#ZU0_G1Z!17G_P#PO+P9_P!!N'\C1_PO+P9_T&X?R-'M8=P^M4/YT>@45Y__
M ,+R\&?]!N'\C1_PO+P9_P!!N'\C1[6'</K5#^='H%%>?_\ "\O!G_0;A_(T
M?\+R\&?]!N'\C1[6'</K5#^='H%%>?\ _"\O!G_0;A_(T?\ "\O!G_0;A_(T
M>UAW#ZU0_G1Z!17G_P#PO+P9_P!!N'\C1_PO+P9_T&X?R-'M8=P^M4/YT>@4
M5Y__ ,+R\&?]!N'\C1_PO+P9_P!!N'\C1[6'</K5#^='H%%>?_\ "\O!G_0;
MA_(T?\+R\&?]!N'\C1[6'</K5#^='H%%>?\ _"\O!G_0;A_(T?\ "\O!G_0;
MA_(T>UAW#ZU0_G1Z!17G_P#PO+P9_P!!N'\C1_PO+P9_T&X?R-'M8=P^M4/Y
MT>@45Y__ ,+R\&?]!N'\C1_PO+P9_P!!N'\C1[6'</K5#^='H%%>?_\ "\O!
MG_0;A_(T?\+R\&?]!N'\C1[6'</K5#^='H%%>?\ _"\O!G_0;A_(T?\ "\O!
MG_0;A_(T>UAW#ZU0_G1Z!17G_P#PO+P9_P!!N'\C1_PO+P9_T&X?R-'M8=P^
MM4/YT>@45Y__ ,+R\&?]!N'\C1_PO+P9_P!!N'\C1[6'</K5#^='H%%>?_\
M"\O!G_0;A_(T?\+R\&?]!N'\C1[6'</K5#^='H%%>?\ _"\O!G_0;A_(T?\
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M</K5#^='H%%>?_\ "\O!G_0;A_(T?\+R\&?]!N'\C1[6'</K5#^='H%%>?\
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M[111RH/9Q[!]C;_GI_X[1]C;_GI_X[111RH/9Q[!]C;_ )Z?^.T?8V_YZ?\
MCM%%'*@]G'L'V-O^>G_CM'V-O^>G_CM%%'*@]G'L'V-O^>G_ ([1]C;_ )Z?
M^.T44<J#V<>P?8V_YZ?^.T?8V_YZ?^.T44<J#V<>P?8V_P">G_CM'V-O^>G_
M ([111RH/9Q[!]C;_GI_X[1]C;_GI_X[111RH/9Q[!]C;_GI_P".T?8V_P">
MG_CM%%'*@]G'L'V-O^>G_CM'V-O^>G_CM%%'*@]G'L'V-O\ GI_X[1]C;_GI
M_P".T44<J#V<>P?8V_YZ?^.T?8V_YZ?^.T44<J#V<>P?8V_YZ?\ CM'V-O\
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1]C;_ )Z?^.T44^5!R1['_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
